From the Directors Report for the Year Ended 30 June 2016, Richard Hopkins completed his employment with Phylogica on October 14, 2016. Who indeed will take the company forward in the transition towards drug development?
In another point from the Directors Report, it was noted that the discovery/screening platform has been reinforced by a deepening collaboration with UQ's IMB and the work on macrocyclic peptides. The term 'deepening' is suggestive of good news on that front at some stage.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |